Search

Three strained Ru(II) metal-organic dyads were prepared and characterized by NMR, mass spectrometry, and analytical HPLC to probe whether these constructs could act as multifunctional photochemotherapy (PCT) agents. The compounds incorporated the crowded 6,6'-dimethyl-2,2'-bipyridine (6,6'-dmb) ligand to impart stoichiometric photocisplatin activity, and imidazo[4,5-f] [1,10]phenanthroline (IP) appended with n thiophene units (nT; n=1-3) to add capacity for singlet oxygen sensitization. With visible light activation, each complex of the series underwent rapid and selective photoejection of 6,6'-dmb in less than 10min, with half-lives (t1/2) as short as 46.3s for [Ru(6,6'-dmb)2(IP-1T)](2+). Photo-triggered ligand loss slowed with increasing n, and was slowest for [Ru(6,6'-dmb)2(IP-3T)](2+) (t1/2=273s). This trend also held for photoadduct formation with DNA; [Ru(6,6'-dmb)2(IP-1T)](2+) produced relaxed circular DNA at the lowest concentrations. Singlet oxygen yields (ΦΔ) increased with n, whereby ΦΔ for [Ru(6,6'-dmb)2(IP-1T)](2+) was only 3%, but increased to 42% on going to [Ru(6,6'-dmb)2(IP-3T)](2+). This photosensitization process was reflected by single-strand breaks in the gel-mobility shift assays of [Ru(6,6'-dmb)2(IP-3T)](2+), but was not discernible for the other compounds. Despite different photochemical and photophysical reactivities, all of the compounds were potent phototoxic agents toward cancer cells (EC50=1-2μM) with relatively short compound-to-light intervals and moderate visible light doses. [Ru(6,6'-dmb)2(IP-3T)](2+) was exceptionally photoactive toward cancer cells at longer intervals (EC50=200nM, PI=750). Phototherapeutic margins increased with n due to decreased dark cytotoxicity for the more π-expansive complexes, making metal-organic dyad [Ru(6,6'-dmb)2(IP-3T)](2+) the best multifunctional PCT agent.

Ru(II) dyads derived from organic units that impart low-lying 3IL excited states combine the most attractive features of organic photosensitizers with those of coordination complexes. The result is a bichromophoric system with excited-state lifetimes that are significantly longer than those associated with traditional 3MLCT states. Incorporation of α-oligothiophenes as the organic chromophore leads to systems that act as dual Type I/II photosensitizers, opening up the possibility of treating hypoxic tumors with photodynamic therapy (PDT) and overcoming problems with in vivo dosimetry. These photosensitizers, particularly those that consist of three thiophene units and higher, are remarkable DNA binders and photocleavers when exposed to light, exhibiting no interference with DNA structural integrity in the absence of a light-trigger. Such light-responsive agents localize in the nuclei of cells without the need for a carrier and produce a potent PDT response with minimal dark toxicity. This phototherapeutic effect translates directly to animals and is superior to the clinical agent Photofrin® in this model. These Ru(II) dyads can be activated with light in the PDT window, despite very low molar extinction coefficients in this region, and this phenomenon can be attributed to the efficiency with which these agents operate. The ability to activate these prodrugs with ultraviolet to near-infrared light marks an unprecedented versatility that can be exploited to match treatment depth to tumor invasion depth without compromising potency, giving rise to photosensitizers for multiwavelength PDT.

Prodigiosenes, possessing a 4-methoxypyrrolyldipyrrin skeleton, are known for their anti-cancer activity. Structural modification of the C-ring resulted in a series of prodigiosenes that displayed promising activity against leukemia cell lines during in vitro analysis against the NCI 60 cancer cell line panel. Further in vivo studies of these compounds using the zebrafish model showed persistence of anti-leukemia properties in human K562 chronic myelogenous leukemia cells.

Analogues of the tripyrrolic natural product prodigiosin bearing an additional methyl and a carbonyl group at the C-ring were synthesised and evaluated. In vitro anticancer activity screening (NCI) and the study of modes of action (copper-mediated cleavage of double-stranded DNA and transmembrane transport of chloride anions) showed that the presence of the methyl group is not detrimental to activity. Furthermore, although the presence of an ester conjugated to the prodigiosene C-ring seems to decrease both pKa and chloride transport efficiency compared to the natural product, these analogues still exhibit a high rate of chloride transport. All analogues exhibit good in vitro anticancer activity and reduced toxicity compared to the natural product: compare an acute systemic toxicity of 100 mg kg−1 in mice vs. 4 mg kg−1 for prodigiosin, pointing towards a larger therapeutic window than for the natural product.

Analogues of the tripyrrolic natural product prodigiosin bearing an additional methyl and a carbonyl group at the C-ring were synthesised and evaluated. In vitro anticancer activity screening (NCI) and the study of modes of action (copper-mediated cleavage of double-stranded DNA and transmembrane transport of chloride anions) showed that the presence of the methyl group is not detrimental to activity. Furthermore, although the presence of an ester conjugated to the prodigiosene C-ring seems to decrease both pK(a) and chloride transport efficiency compared to the natural product, these analogues still exhibit a high rate of chloride transport. All analogues exhibit good in vitro anticancer activity and reduced toxicity compared to the natural product: compare an acute systemic toxicity of 100 mg kg(-1) in mice vs. 4 mg kg(-1) for prodigiosin, pointing towards a larger therapeutic window than for the natural product.